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TemozolomideAbstract Aims: Glioblastoma (GBM) is the most common and aggressive primary malignant
brain tumour in adults, with a poor prognosis. Changing treatment paradigms suggest
improved outcome, but whole nation data for England is scarce. The aim of this report is
to examine the incidence of patients with glioblastoma in England, and to assess the inﬂuence
of gender, age, geographical region and treatment on outcome.
Methods: A search strategy encompassing all patients coded with GBM and treated from Jan-
uary 2007 to December 2011 was obtained from data linkage between the National Cancer
Registration Service and Hospital Episode Statistics for England.
Results: There were 10,743 patients coded with GBM in this 5-year period (6451 male, 4292
female), giving an overall national age standardised incidence of 4.64/100,000/year. Incidence
increases with age. Median survival overall was 6.1 months. One, 2 and 5-year survivals, were
28.4%, 11.5% and 3.4% respectively. Age stratiﬁed median survivals decreased signiﬁcantly
(p < 0.0001) with increasing age from 16.2 months for the 20–44 year age group, to 7.9 months
for the 45–69 years, and 3.2 months for 70+ years. In the maximal treatment subgroup,
patients aged up to 69 years had a median survival of 14.9 months. Patients over 60 years were
less likely to receive maximal combination treatment but median survival was better with max-
imal treatment at all ages.inters),
534 A. Brodbelt et al. / European Journal of Cancer 51 (2015) 533–542Conclusions: The overall outcome for patients with GBM remains poor. However, aggressive
treatment at every age group is associated with extended survival similar to that described in
clinical trials.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioblastoma (GBM: World Health Organisation
(WHO) grade IV glioma) is the most common and
aggressive primary malignant brain tumour in adults
[1]. The international estimated age adjusted incidence
for all patients with primary malignant brain tumours
(not exclusively GBM) is 5.3 per 100,000 population
with higher rates in some western developed countries
[2]. Few patients with GBM survive long term with
reported median survivals of 6–9 months (Johnson,
2012, Darefsky, 2012).
In 2005 an European Organisation for Research and
Treatment of Cancer and the National Cancer Institute
of Canada Clinical Trials Group (EORTC/NCIC) phase
III randomised trial showed the beneﬁt of adding con-
current and adjuvant temozolomide, an oral alkylating
agent that penetrates the blood brain barrier, to radio-
therapy with a median survival of 14.6 months and 5-
year survival of 9.8% [3,4]. Since publication, this proto-
col has become the standard of care for patients with
GBM. Reports suggest an improvement in outcome
since the widespread introduction of temozolomide after
2005, but complete whole country data for England is
scarce. Only one previous national study examined the
cancer journey of patients diagnosed with glioblastoma
and treated in 2004–2005 in England and reported
21% 1-year survival [5]. The impact of the introduction
of temozolomide on the combined patient outcome
may be less than predicted as incidence peaks in the
elderly, yet patients older than 70 years were not
recruited to the EORTC/NCIC trial, and many may
not receive temozolomide [3].
Between 2011 and 2013 English cancer registry data
were centralised allowing ready exploration of national
data on patients with brain tumours across the whole
of England for the ﬁrst time (approx 53.5 million people
in 2012, Oﬃce for National Statistics 2013). These data
are linked to data on hospital admissions (Hospital epi-
sode statistics: HES), which include treatment related to
surgery, chemotherapy and pathology and radiology
reports. In addition, multidisciplinary team meetings
(MDTs; or tumour boards) feed diagnostic and therapy
data directly to the National Cancer Registration Ser-
vice (NCRS). This makes England uncommon in having
detailed whole nation incidence and treatment data for
all patients diagnosed with cancer. Here, we report the
incidence and survival of patients with GBM in England
2007–2011 (Inclusive), and examine the relationshipbetween age, sex, geographical region, treatment and
outcome.2. Methods
2.1. Patient cohort
We included all patients diagnosed with cranial glio-
blastoma (ICD10 site: C71, ICDO2 morphology 9440/3,
9441/3 and 9442/3) between 1st Jan 2007 and 30th Dec
2011, who were resident in England as registered by the
NCRS. The NCRS holds data collated from electronic
and paper-based reports, clinical notes, pathology
reports and HES records (http://www.hscic.gov.uk/
hes), which reports diagnosis as ICD-10 code and proce-
dures using OPCS 4 (UK national classiﬁcation of inter-
ventions and procedures version 4: http://systems.hscic.
gov.uk/data/clinical coding/codingstandards/opcs4) for
all patients admitted to hospital. Chemotherapy linked
data describe treatment provision but not type, and
company data provide unlinked temozolomide sales in
England. Radiotherapy data are only complete from
2012 and were not used in this analysis. Data elements
include age at diagnosis, tumour site, morphology,
behaviour, WHO grade and treatment.
Vital status was checked using the NHS Personal
Demographics Service (PDS) (http://systems.hscic.gov.
uk/demographics/pds/). In this analysis, surgery encom-
passes all debulking procedures but not biopsy. HES
data linkage were not complete but in eight of the nine
regions were over 93%. The East of England (HES
linkage 83%) used patient admission statistics (PAS) as
the main source of hospital treatment data so would
not normally match their data to HES. There was no
signiﬁcant diﬀerence between year of diagnosis, age
and degree of linkage. Unlinked data between HES
and NCRS were included in the analysis as other
sources of treatment data including PAS, hospital notes
and path reports could be used.2.2. Statistical analysis
Annual European Age Standardised Incidence rates
per 100,000 population were calculated for overall and
age speciﬁc cohorts, using standard techniques. The stan-
dard population used is the 2013 European Standard
Population (Annex F, http://epp.eurostat.ec.europa.
eu/cache/ITY_OFFPUB/KS-RA-13-028/EN/KS-RA-
13-028-EN.PDF) and the maximum age band is 85+.
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ardised incidence rates were calculated using Dobson &
Byar’s method [6]. For comparison with the data from
the US, the standard population used was the 2000 US
Standard Population available from http://seer.cancer.
gov/stdpopulations/stdpop.19ages.html [7].
Median survival in months and one, 2 and 5-year
overall survival percentages were calculated using the
stci and strs (www.pauldickman.com/rsmodel/stata_
colon/) commands respectively in Stata version 12 SE
(http://www.stata.com). A diﬀerence was considered
statistically signiﬁcant when the p-value was <0.05, or
when the 95% conﬁdence intervals did not overlap.
Treatment analysis examined 2007–2010 inclusive
because linked treatment data were currently available
only for diagnosis up to the end of 2010. As those over
70 years of age were less likely to be given temozolo-
mide, and their prognosis was poor, they were excluded
from Fig. 6 and Tables 2 and 3 purely to allow a clearer
comparison of the implications of treatment with less
age eﬀect.3. Results
There were 10,743 patients registered with GBM in
England from 2007 to 2011 (6451 male, 4292 female),
giving an overall national age standardised incidence
of 4.64/100,000/year (Table 1). Men had an incidence
1.66 times that of women. The frontal lobe was the most
common site recorded (24.9%) followed by the temporal
lobe (21.8%), parietal lobe (16.7%), occipital lobe
(4.8%), cerebellum (0.5%), brain stem (0.4%) or was
not speciﬁed/other (30.9%). There was no change in
age standardised incidence or tumour site over the
5 years studied. Incidence increases with age, with a
peak between 65 and 75 years of age (Fig. 1). More than
90% of patients had histological conﬁrmation of their
diagnosis, although this is less than 60% in the 70+
age group (Fig. 2). Median survival was 6.1 months
overall, and 1, 2 and 5-year survivals were 28.4%,
11.5% and 3.4% overall (Table 1, Fig. 3). There was
no diﬀerence between male and female outcome
(p = 0.22). Survival worsens with increasing age band
(Fig. 4). Median survival for patients age 20–44 wasTable 1
Incidence and survival for patients with glioblastoma by sex: 2007–2011. AS
months. Figures in brackets are 95% conﬁdence intervals.
2007 2008 2009
Male count 1243 1291 1287
Male ASR 5.81 (5.49–6.15) 5.94 (5.62–6.28) 5.83 (5.
Male median survival 6.6 (5.9–7.1) 6.4 (5.7–6.9) 6.7 (6.0
Female count 803 870 846
Female ASR 3.41 (3.18–3.66) 3.64 (3.40–3.89) 3.49 (3.
Female median survival 5.3 (4.7–6.1) 5.6 (4.8–6.1) 5.8 (5.3
Persons count 2046 2161 2133
Persons ASR 4.54 (4.34–4.74) 4.73 (4.53–4.94) 4.61 (4.
Persons median survival 6.0 (5.6–6.5) 6.0 (5.6–6.4) 6.2 (5.816.2 months, for those aged 45–69 was 7.2 months,
and for those age 70+ was 3.2 months (Fig. 5). Median
survival by site showed that patients with tumours in the
temporal (8.2 months), occipital (8.1 months), frontal
(7.1 months) and parietal (6.6 months) lobes did better
than those in the cerebellum (4.0 months), ventricle
(4.3 months) or unspeciﬁed (3.8 months) (p < 0.0001).
There were signiﬁcant diﬀerences in outcome between
all treatment groups (p < 0.0001) (Fig. 6 and Table 2).
To better examine the diﬀerences in outcome by treat-
ment modality, only patients aged up to and including
70 years (2007–2010 inclusive; n = 5995) were included
in this part of the analysis. The survival advantages of
re-operation, re-irradiation or second or third line
chemotherapy were not examined. Radiotherapy data
are not complete, but it is likely that most patients
who had surgery and chemotherapy also had radiother-
apy (Johnson, 2012, Darefsky, 2012). Patients who had
chemotherapy (Groups 3 and 4) lived longer than
patients who did not (Groups 1 and 2), although the
chemotherapy groups were of younger age. It is not
possible to say exactly how many of these patients with
GBM received temozolomide, but sales data suggest
that most of the 660 patients per year under 70 who
had chemotherapy had temozolomide. This calculation
comes from company ﬁgures that 47,141 to 66,885 packs
of ﬁve are sold per year (Source: IMS Health, IMS
Health Hospital Pharmacy Audit by Country (HPAIC)
MAT 2007–2011 Units: Total molecule usage through
English hospital pharmacies based on projected sample
data as interpreted by MSD Ltd). An 80 kg 170 cm male
has a surface area of 2 m2. The concomitant phase of
42 days of 75 mg/m2 requires 150 mg/day which equates
to 1  140 mg tablet and 2  5 mg tablets or 3  9
packs = 27 packs. The adjuvant phase of 150 mg/m2
or 300 mg/day for 5 days for six cycles equates to
2  140 mg tablets and 1  20 mg tablets so a further
18 packs. Depending on the exact dose required, this
means approximately 40–70 packs of ﬁve are required
for treatment, so approximately 1000 patients per year.
Some patients with anaplastic astrocytoma will be
treated with temozolomide, but this still suggests most
of the 660 patients who are reported to have had chemo-
therapy probably had temozolomide.R: Age standardised rate per 100,000 population. Median survival is in
2010 2011 Average 2007–2011
1263 1367 1290
51–6.16) 5.71 (5.40–6.04) 6.04 (5.72–6.38) 5.87 (5.73–6.02)
–7.2) 6.1 (5.6–6.6) 6.9 (6.4–7.6) 6.5 (6.2–6.8)
834 939 858
26–3.73) 3.40 (3.17–3.64) 3.77 (3.53–4.02) 3.54 (3.44–3.65)
–6.3) 5.5 (4.9–6.1) 5.6 (5.0–6.2) 5.6 (5.3–5.8)
2097 2306 2149
41–4.81) 4.49 (4.30–4.69) 4.84 (4.65–5.05) 4.64 (4.56–4.73)
–6.8) 5.8 (5.5–6.3) 6.3 (5.8–6.8) 6.1 (5.9–6.3)
Fig. 1. Age speciﬁc incidence and total numbers of glioblastoma by 5 year age band between 2007 and 2011. Total numbers of patients presenting
with glioblastoma between 2007 and 2011 by age (Right hand scale). Age speciﬁc incidence of patients by sex with glioblastoma per 100,000
population (left hand scale). Numbers peak between 60 and 70 years of age, whilst the incidence peaks between 65 and 75 years.
Fig. 2. Relative rates of basis of diagnosis by age. The Majority of diagnoses are based on histology, with only 0.85% based on the death certiﬁcate
only, and these cases were included in the analysis. Histological veriﬁcation rates were lower in the 70+ age range.
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and probably radiotherapy, were deﬁned as having max-
imal treatment (group 4). Thirty four percent of the total
group had maximal treatment, although there was vari-
ation with age, including only 12% of the 70–74 year old
group, 3% of the 75–79 year old group and just two
patients of 577 (<1%) in the 80+ age group (Fig. 7).
There was a longer median survival in the maximally
treated group at all ages, but this did not abolish the
stratiﬁed association with age (Fig. 8).Regional variation appears to exist, although regio-
nal data quality issues may play a role (Table 3).
Reported numbers for ‘glioma or malignant brain
tumour not otherwise speciﬁed’ were high in the South
West (36%) and low in the East Midlands (19%), and
some of these patients are likely to have a GBM, aﬀect-
ing the reported incidence levels.
There were 135 patients age up to 18 years of age,
with the cerebral hemispheres remaining the most
common site (63%), followed by the brainstem (13%).
Fig. 3. Kaplan–Meier plot showing survival for patients with a glioblastoma. Median life expectancies are 56 months for women, 65 for men, and
61 overall. One, 2 and 5-year survivals were 292%, 109% and 30% for men, 273%, 125% and 41% for women, and 284%, 115% and 34%
respectively overall.
Fig. 4. Median life expectancy in months for patients with a GBM by age. There is a signiﬁcant stepwise reduction in life expectancy with
increasing age P20 years (p < 00001). Bars denote 95% conﬁdence intervals.
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patients, with one, two and ﬁve survivals of 50.5%,
25.8% and 15.4% respectively.
4. Discussion
Interest in the treatment and outcome for patients
with glioblastoma has increased with better treatment
paradigms and an improved understanding of the molec-
ular subtypes [3,8,9]. In the US, the age standardised
incidence for GBM is 3.19 [7]. Estimates for other coun-
tries are often lower [2]. Using the English incidence forGBM but standardised against the US population to
allow direct comparison gives a ﬁgure of 3.43 per
100,000 population for England. Both this ﬁgure and
the European age adjusted incidence of 4.64 per
100,000 population appear to place England amongst
the higher rates in the world, but this may relate to inter-
national variations in coding and diagnostic practice
rather than fundamental underlying diﬀerences.
Although no alteration was found in glioblastoma inci-
dence between 2007 and 2011, debate exists regarding
changing prevalence, with some studies suggesting an
increase and other model based estimates suggesting
Fig. 5. Kaplan–Meier plot demonstrating survival by age. Survival decreases signiﬁcantly (p < 00001) for each increasing age band. Median
survivals for age 20–44, 45–69 and 70+ were 16.2 months, 7.9 months and 3.2 months respectively. One, 2 and 5-year survivals for age 20–44 were
611%, 377% and 154%, for age 45–69 were 343%, 129% and 31%, and for age 70+ were 78%, 15% and 05% respectively (p < 00001).
Fig. 6. Kaplan–Meier plot demonstrating survival by treatment type for patients with glioblastoma 20–70 years of age (2007–2010). RT:
Radiotherapy. Radiotherapy data is not complete, but it is likely that most of the patients in groups 2–4 under 70 years of age received
radiotherapy. Chemo: Chemotherapy. Surgery is any debulking procedure and does not include biopsy. There were signiﬁcant diﬀerences between
all treatment groups (p < 00001).
538 A. Brodbelt et al. / European Journal of Cancer 51 (2015) 533–542stability [10,11]. A male preponderance of GBM is
described previously, and the relative sex ratio is similar
in England (1.66) to the US (1.56) [2,10,12,13].
Regional variation in brain tumour patient incidence
and survival has been examined previously. A study of
894 patients in Southern England in 1976 suggested an
increased incidence in rural or smaller (<50,000) urban
communities [12]. Incidence data presented in the cur-
rent report are aﬀected by diﬀerent coding practices
and age variations, limiting valid comparisons. These
variations do not aﬀect survival data, and poor survivalin the Southeast of England may be related to the low
percentage of patients having maximal treatment. The
lowest maximal treatment rates were seen in London
but did not correspond to low median survival rates.
This discrepancy may be related to the younger aged
population and poor data return for this item in
London.
Outcome for patients with GBM is poor, in line with
other western countries [11,14–16]. US data uses the
SEER database, which covers 26% of the total popula-
tion [7]. Published median survival rates in the US vary,
Table 2
Survival by treatment type for patients with glioblastoma aged 20–70 years of age (2007–2010). RT: Radiotherapy. Surgery: surgical debulking
only. Chemo: chemotherapy. Bx: Biopsy. Figures following median, one, two and ﬁve-year survivals are 95% conﬁdence intervals.
Group Description Number of
patients
Average
age
Median survival/
months
1 Year
survival
2 Year
survival
5 Year
survival
1 No treatment or RT alone
(minimal treatment)
1708 59.1 3.0 (2.8–3.1) 15.3% (13.6–
17.1%)
6.6% (5.4–
7.8%)
2.6% (1.8–
3.5%)
2 Surgery ± RT (palliative
surgery)
1645 59.0 5.2 (3.9–5.4) 20.1% (18.2–
22.0%)
6.7% (5.6–
8.0%)
3.0% (2.2–
4.0%)
3 Bx + Chemo ± RT (non-
surgical treatment)
634 54.7 10.1 (9.4–11.2) 45.8% (42.0–
49.6%)
17.4% (14.6–
20.5%)
6.0% (4.2–
8.2%)
4 Surgery + Chemo ± RT
(maximal treatment)
2008 55.1 14.8 (14.2–15.4) 63.4% (61.3–
65.5%)
28.7% (26.7–
30.6%)
6.6% (5.3–
8.0%)
5 All cases combined 5995 57.3 6.0 (5.8–6.2) 36.2% (35.0–
37.4%)
15.3% (14.4–
16.2%)
4.5% (3.9–
5.1%)
Fig. 7. Percentage of patients with GBM treated with Surgery, Chemotherapy, +/ radiotherapy (RT) by age: 2007–2010. Radiotherapy data is
not complete, but it is likely that most of the patients in this group under 70 years of age received radiotherapy.
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between 5.7 and 9.7 months [14–16]. One, 2 and 5-year
survival rates in the US are quoted as being 35%,
13.7% and 4.7% rather than the English values of
28.4%, 11.5% and 3.4% respectively [7,14]. Because of
the diﬀerence in populations, comparison of age range
groups may be more accurate when comparing with
US data. Age groups compare favourably between
CBTRUS and English data for 1 and 2-year survivals,
with better 5-year survival ﬁgures for England.
Increasing age is known as a poor prognostic factor
for patients with GBM [7,16]. There is a stratiﬁed rela-
tionship between ﬁve year age increases between 30
and 85, and reduced median survival by 0.5–4.0 months
for every age increment. This steady deterioration in
overall survival does not take into account performance
score, comorbidity, tumour biomarkers or the molecular
variants of glioblastoma identiﬁed over the last few
years that are found in diﬀerent age ranges [8,9,17].The absence of radiotherapy data and the failure to
deﬁne linked chemotherapy type are weaknesses of this
report. Studies using the SEER database show three
quarters of US patients receive radiotherapy, and if no
radiotherapy is given then median survivals are only
3 months [14,16]. As the current standard of care sup-
ports radiotherapy with other treatment options, and
radiotherapy is relatively cheap to provide, is readily
available, andmedian survival approaches theUSﬁgures,
it is likely that English radiotherapy rates are similar to
those seen in the US. The one quarter that did not receive
radiotherapy are likely to bemainly within the elderly and
minimal treatment groups, where survivals are poor.
Temozolomide chemotherapy has been the standard of
care since 2005, and other authors have assumed its use
when describing unspeciﬁed chemotherapy provision
[14,16]. Although only an estimate, the pack sales data
suggest a substantial proportion of patients who received
chemotherapy received temozolomide.
Fig. 8. Median survival of all patients by age compared to those treated with surgery, chemotherapy (Chemo), +/ radiotherapy (RT): 2007–2010.
Radiotherapy data is not complete, but it is likely that most of the patients in this group under 70 years of age received radiotherapy.
Table 3
Regional variation in incidence, outcome and treatment 2007–2011. Incidence is per 100,000 population.
Figures describe outcome as median life expectancy in months. Figures in brackets are 95% conﬁdence
intervals, except for Surgery + Chemo rates were brackets indicate absolute numbers. Surgery + Chemo
are predicted rates for surgery, temozolomide and radiotherapy, for age 20–70 years inclusive, and are
from the years 2007–2010 only. Lowest incidence, highest survival and surgery + chemo rates shown in
shaded boxes, and highest incidence and lowest survival and surgical rates are shown in bold.
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maximal treatment, whilst a further 10% received
chemotherapy with a biopsy. This means that less than
half of all patients with GBM in England received the
current standard of care. This may be due to signiﬁcant
numbers of elderly and poor performance patients not
receiving this treatment. There is little population data
available for comparison. The SEER database does
not include chemotherapy data, so reports on US
outcomes assume temozolomide use and do not provide
comparable percentage ﬁgures [14,16].
There were relatively few paediatric patients in the
time frame examined (1% of total). Brainstem glioblas-
toma was much more common in paediatric patients
than adults, but this ﬁgure is probably an underestimate
as diﬀuse pontine gliomas were not included. One, two
and ﬁve year survivals were only slightly lower for
England for age under 20 years than the US being
50.5%, 25.8% and 15.4% for England and 57.2%,
32.5% and 12.6% for the US respectively [7]. This age
group did less well than the young adult [20–44]. This
may relate to tumour position, as more brain stem
tumours are seen in the paediatric population, diﬃculties
with radiotherapy morbidity in the younger child, and a
diﬀerent paediatric genetic glioblastoma subtype [7,9].
English median survival ﬁgures for patients having
maximal treatment (group 4, 14.9 months, 95% CI:
14.2–15.4) compare favourably with those from the
EORTC trial (14.6 months) [3]. In the EORTC trial,
84% of patients had debulking surgery and this group
had a median survival of 15.8 months as compared to
9.4 months for those that had a biopsy alone [3].
The elderly do poorly. Elderly patients are less likely
to receive aggressive treatment, or get histological veriﬁ-
cation of the tumour type, and have poor median surviv-
als [18]. Poor survival may be due in part to the variable
underlying molecular genetics of the tumour group that
is called GBM, in that older people tend to get less
favourable subtypes [19–21]. The NOA-08 and Nordic
phase III trials examined temozolomide treatment alone
compared to radiotherapy alone and found no signiﬁ-
cant diﬀerence in outcome [22,23]. MGMT promotor
methylation was associated with longer survival in
patients treated with temozolomide alone, supporting
its use in a decision pathway between temozolomide
and radiotherapy [22,23]. Despite poor outcomes overall
in the elderly, there appears a further survival advantage
in those treated with combination surgery, chemother-
apy, and radiotherapy, either due to careful patient
selection or favourable molecular subtyping [18,24,25].
Quality of life data were not examined in the present
study, and might mitigate slight increases in life expec-
tancy. Outcomes in elderly patients treated without che-
motherapy appear so poor that appropriately counselled
patients may prefer palliative care rather than treatment
regimes that will occupy much of the rest of their lives,and risk treatment related side-eﬀects. The notion that a
strict age cut oﬀ exists at age 65 or 70 cannot be
supported by the steady decline seen in survival.
In conclusion, although median survival for patients
with GBM in England is only 6 months, aggressive
treatment at all ages is associated with extended survival
similar to that described in clinical trials. Improved
data quality currently being achieved will allow more
searching analyses to be possible in the near future.Funding
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